Here are four key points:
1. The bone graft is composed of a synthetic small peptide and anorganic bone mineral.
2. i-Factor fosters a favorable environment that enhances cell attachment to the ABM scaffold.
3. The FDA approved i-Factor, which is the first approved bone graft for the cervical spine.
4. In a clinical trial, i-Factor demonstrated a 69 percent success rate for all four outcomes compared to a 57 percent success rate for autograft.
More articles on devices:
St. Jude Medical launches Axium Neurostimulator System — 5 highlights
JRI Orthopaedics, RESTORATION develop 3D printed bioceramic implant — 4 highlights
Stryker Spine acquires SafeWire, builds on MIS presence — 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
